← back to search

Guozhong Jiang

Zhengzhou University · CN
Area of research
Surgery · Cancer Research
Research interest
Research topics from publications: Potent and specific MTH1 inhibitors targeting gastric cancer; Clinical evaluation of a multitarget fecal immunochemical test‐sDNA test for colorectal cancer screening in a high‐risk population: a prospective, multicenter clinical study. Representative work: Abstract Human mutT homolog 1(MTH1), the oxidized dNTP pool sanitizer enzyme, has been reported to be highly expressed in various malignant tumors. However, the oncogenic role of MTH1 in gastric cancer remains to be determined. In the current study, we found that MTH1 was overexpressed in human gastric cancer tissues and cells. Using an in vitro MTH1 inhibitor screening system, the compounds available in our laboratory were screened and the small molecules containing 5-cyano-6-phenylpyrimidine structure were firstly found to show potently and specifically inhibitory effect on MTH1, especially compound MI-743 with IC 50 = 91.44 ± 1.45 nM. Both molecular docking and target engagement experimen Abstract Colorectal cancer (CRC) is a major malignancy threatening the health of people in China and screening could be effective for preventing the occurrence and reducing the mortality of CRC. We conducted a multicenter, prospective clinical study which recruited 4,245 high‐risk CRC individuals defined as having positive risk‐adapted scores or fecal immunochemical test (FIT) results, to evaluate the clinical performance of the multitarget fecal immunochemical and stool DNA (FIT‐sDNA) test for CRC screening. Each participant was asked to provide a stool sample prior to bowel preparation, and FIT‐sDNA test and FIT were performed independently of colonoscopy. We found that 186 (4.4%) were con
h-index
citations
0
works
0
NIH funding
primary concept
email

Recent publications

Clinical evaluation of a multitarget fecal immunochemical test‐sDNA test for colorectal cancer screening in a high‐risk population: a prospective, multicenter clinical study
MedComm 2023cited by 8position: middledoi
Potent and specific MTH1 inhibitors targeting gastric cancer
Cell Death and Disease 2019cited by 32position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Qian Xiao · Zhejiang Cancer Hospital1 papers (2023–2023)Yi‐Chao Zheng · University of Michigan–Ann Arbor1 papers (2019–2019)Tinghan Yang · Sichuan University1 papers (2023–2023)Hui Qiao · Boston University1 papers (2019–2019)Shu Zheng · Ministry of Education of the People's Republic of China1 papers (2023–2023)Zhihua Tao · University of Alabama at Birmingham1 papers (2023–2023)Jing Yang · Agency for Science, Technology and Research1 papers (2019–2019)Chunbao Zhai · Shanxi Medical University1 papers (2023–2023)Kefeng Ding · Ministry of Education of the People's Republic of China1 papers (2023–2023)Liyun Niu · Shanxi Medical University1 papers (2023–2023)Xiaofeng Chen · Ningbo University1 papers (2023–2023)Qing Wang · Guangxi Zhuang Autonomous Region Health and Family Planning1 papers (2023–2023)Junwei Wang · The First Affiliated Hospital, Sun Yat-sen University1 papers (2019–2019)Qian Guo · Fudan University1 papers (2019–2019)Lingyu Li · Hospital for Sick Children1 papers (2019–2019)Hong‐Min Liu · Ministry of Education1 papers (2019–2019)Xiangxing Kong · Zhejiang University1 papers (2023–2023)Wen Zhao · Columbia University1 papers (2019–2019)Sanjun Cai · Fudan University1 papers (2023–2023)Gang Liu · Guangzhou University of Chinese Medicine1 papers (2023–2023)